EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

NCT07434713 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Age-Related Macular Degeneration (AMD)

Interventions

DRUG: treatment with Aflibercept 8mg (Eylea)

Sponsor

Insel Gruppe AG, University Hospital Bern